Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: A possible modulatory role in natural killer cytotoxicity

American Journal of Pathology

Volumn 154, Issue 2, 1999, Pages 457-468

  Kataoka, Hiroaki ^a   Uchino, Hirofumi ^a   Iwamura, Takeshi ^a   Seiki, Motoharu ^b   Nabeshima, Kazuki ^a   Koono, Masashi ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEINASE INHIBITION; TUMOR VOLUME;

EID: 0032912952     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65292-3     Document Type: Article

References (45)

1. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinase and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996, 7:147-154
2. Desrochers PE, Jeffrey JJ, Weiss SJ: Interstitial collagenase (matrix metalloproteinase-1) expresses sepinase activity. J Clin Invest 1991, 87:2258-2265
3. 1 antitrypsin by human stromelysin. FEBS Lett 1991, 279:91-94
4. 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994, 1199:224-228
5. Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG, Senior RM: Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α1-antitrypsin. Biochem Biophys Res Commun 1994, 204:613-620
6. Pei D, Majmudar G, Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 1994, 269:25849-25855
7. 1-antitrypsin secreted by human adenocarcinoma cell lines. FEBS Lett 1993, 328: 291-295
8. Karashima S, Kataoka H, Itoh H, Maruyama R, Koono M: Prognostic significance of α-1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer 1990, 45:244-250
9. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R: An evaluation of the prognostic significance of α-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer 1992, 65:300-302
10. Allgayer H, Babic R, Grutzner KU, Beyer BCM, Tarabichi A, Schildberg FW, Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998, 16:62-73
11. Noël AC, Lefebvre O, Maquoi E, VanHoorde L, Chenard M-P, Mareel M, Foidart J-M, Basset P, Rio M-C: Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 1996, 97:1924-1930
12. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994, 54:4805-4812
13. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997 94:1402-1407
14. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270
15. Brittenden J, Heys SD, Ross J, Eremin O: Natural killer cells and cancer. Cancer 1996, 77:1226-1243
16. Cercek L, Cercek B: Cancer-associated SCM-recognition, immune defence suppression, and serine protease protection petide. I. Isolation, amino acid sequence, homology, and origin. Cancer Detect Prev 1992, 16:305-319
17. Cercek L, Cercek B: Cancer-associated SCM-recognition, immune defence suppression, and serine protease protection peptide. II. Immunodefense suppressive effects of the CRISPPs peptide. Cancer Detect Prev 1993, 17:433-445
18. Iwamura T, Taniguchi S, Kitamura N, Yamanari H, Kojima A, Hidaka K, Setoguchi T, Katsuki T: Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J. Gastroenterol Hepatol 1992, 7:512-519
19. Taniguchi S, Iwamura T, Katsuki T: Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992, 10:259-266
20. Kataoka H, Seguchi K, Iwamura T, Moriyama T, Nabeshima K, Koono M: Reverse-zymographic analysis of protease nexin-ll/amyloid β protein precursor of human carcinoma cell lines, with special reference to the grade of differentiation and metastatic phenotype. Int J Cancer 1995, 60:123-128
21. Kataoka H, Nabeshima K, Komada N, Koono M: New human colorectal carcinoma cell lines that secrete proteinase inhibitors in vitro. Virchows Arch B Cell Pathol 1989, 57:157-165
22. Kataoka H, Meng J-Y, Uchino H, Nabeshima K, Kihira Y, Matuo Y, Koono M: Modulation of matrix metalloproteinase-7 (matrilysin) secretion in coculture of human colon carcinoma cells with fibroblasts from orthotopic and ectopic organs. Oncol Res 1997, 9:101-109
23. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N: In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981, 127:34-38
24. Ishihara S, Okayama A, Nagatomo Y, Murai K, Yamashita R, Okamoto M, Shima T, Sasaki T, Mueller N, Tachibana N, Tsubouchi H: Enhanced engraftment of HTLV-I-infected human T cells in severe combined immunodeficiency mice by anti-asialo GM-1 antibody treatment. Microbiol Immunol 1996, 40:39-44
25. Cercek L, Siaw M, Cercek B, Cercek B: A DNA probe study on the origin of the cancer recognition, immune defense suppression and serine protease protection peptide. Cancer Detect Prev 1995, 19:325-330
26. Mallya SK, Hall JE, Lee H-M, Roemer EJ, Simon SR, Golub LM: Interaction of matrix metalloproteinases with serine protease inhibitors. Ann NY Acad Sci 1994, 732:303-314
27. Cercek L, Cercek B: Apparent tumor specificity with the SCM test. Br J Cancer 1975, 31:252-253
28. Cercek L, Cercek B: Changes in SCM-responses of lymphocytes in mice after implantation with Ehrlich ascites cells. Eur J Cancer 1981, 17:167-171
29. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990, 87:3753-3757
30. Joslin G, Fallon RJ, Bullock J, Adams SP, Perlmutter DH: The SEC receptor recognizes a pentapeptide neo-domain of α-1-antitrypsin-protease complexes. J Biol Chem 1991, 266:11281-11288
31. Perlmutter DH: The SEC receptor: a possible link between neonatal hepatitis in α1-antitrypsin deficiency and Alzheimer's disease. Pediatr Res 1994, 36:271-277
32. 1-Proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J Biol Chem 1988, 263:4481-4484
33. Joslin G, Griffin GL, Adams SP, Fallon RJ, Senior RM, Perlmutter DH: The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of α-1-antitrypsin-elastase complexes and amyloid-β peptide. J Clin Invest 1992, 90:1150-1154
34. 2+ in neutrophil-like HL-60 cells: effect of chemotactic peptide antagonist BocMLF. Peptides 1995, 16:1019-1024
35. Arora PK, Miller HC, Aronson LD: α1-Antitrypsin is an effector of immunological stasis. Nature 1978, 274:589-590
36. 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity. Scand J Immunol 1982, 15:109-113
37. Laine A, Leroy A, Hachulla E, Davril M, Dessaint J-P: Comparison of the effects of purified human α1-antichymotrypsin and α1-proteinase inhibitor on NK cytotoxicity. Only α1-proteinase inhibitor inhibits natural killing. Clin Chim Acta 1990, 190:163-174
38. 2-macroglobulin in human gastric carcinomas: a retrospective immunohistochemical study. Hum Pathol 1984, 15:957-964
39. 1-proteinase inhibitor. Biol Chem Hoppe-Seyler 1996, 377:301-311
40. McDonnell S, Navre M, Coffey RJ, Matrisian LM: Expression and localization of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991, 4:527-533
41. Knox JD, Wolf C, McDaniel K, Clark V, Lonot M, Bowden GT, Nagle RB: Matrilysin expression in human prostate carcinoma. Mol Carcinog 1996, 15:57-63
42. Bolon I, Devouassoux M, Robert C, Moro D, Brambilla C, Brambilla E: Expression of urokinase-type plasminogen activator, stromelysin 1 stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 1997, 150:1619-1629
43. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348:699-704
44. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio M-C, Eber M, Mothlin G, Chambon P, Basset P: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993, 53:165-169
45. Ahmad A, Hanby A, Dublin E, Poulsom R, Smith P, Barnes D, Rubens R, Anglard P, Hart I: Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 1998, 152:721-728